about
Clinical Impact of the Immunome in Lymphoid Malignancies: The Role of Myeloid-Derived Suppressor CellsMesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia PatientsProteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia.Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferationOverexpression of heme oxygenase-1 increases human osteoblast stem cell differentiation.Myeloid derived suppressor cells in chronic myeloid leukemia.Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM)Neuroactive molecules and growth factors modulate cytoskeletal protein expression during astroglial cell proliferation and differentiation in culture.Modulation of extracellular signal-related kinase, cyclin D1, glial fibrillary acidic protein, and vimentin expression in estradiol-pretreated astrocyte cultures treated with competence and progression growth factors.The Heme Oxygenase System in Hematological Malignancies.Effect of Lipoic Acid on the Biochemical Mechanisms of Resistance to Bortezomib in SH-SY5Y Neuroblastoma Cells.Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells.Biochemical and clinical relevance of alpha lipoic acid: antioxidant and anti-inflammatory activity, molecular pathways and therapeutic potential.Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells.Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)Heme oxygenase-1 nuclear translocation regulates bortezomibinduced cytotoxicity and mediates genomic instability in myeloma cells.The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma.Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias.A cytoprotective role for the heme oxygenase-1/CO pathway during neural differentiation of human mesenchymal stem cells.Antimicrobial and Anti-Proliferative Effects of Skin Mucus Derived from Dasyatis pastinaca (Linnaeus, 1758).Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib.BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint.PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy.Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donorsHeme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib
P50
Q28083973-2A26E4D3-1167-43F5-9308-541F3012BF45Q28552532-88F03D14-DABE-4440-8311-7BF8122C958DQ33603472-522E53D6-B217-451D-9411-5B77524ABE9EQ33889439-ADC4F7EF-53C7-4240-95BC-A3A6078AA9F2Q34577489-3EB04C59-EA2B-4680-927E-173DC6B699A6Q34775933-51EFEA22-B0F6-447C-9597-FC82BB77018CQ35609094-9710039E-00B0-4AD7-9024-6ED2E8B27DCEQ37373848-BBAA2F43-8665-4E5E-9692-2AA9AC70E750Q38401926-74E5B100-4988-4C4A-BD37-B089816E4BEFQ38410247-146A8D0E-B6CD-4611-B7DD-71DFCFF89AECQ38751020-D61E1B1E-0896-4CA0-8A5D-93F09A74D54CQ38790184-6A80D4E2-1448-42DE-9656-3249E35E3FA7Q38822625-44E3990B-BDE7-43B1-9B01-AA2FCC074EB9Q39414338-EADF7B4D-B7BB-4F0B-B032-0D36872709F3Q39612979-8F8474E5-E806-41D3-AF35-68C9E575D7A7Q39928926-A0E9E050-93C5-43B1-8CCE-4235CFAF1AC9Q39956732-739E6CDA-9E94-46E7-B71F-42823284F1B7Q42317563-C36C3ED9-9828-4A69-B03D-B4FB11CA9489Q43258298-9ED72F2D-C5FB-4DB6-B604-BF029838C37CQ46669773-D8B97654-B707-49CC-AA5C-4C05953DB5A6Q47103329-753B06CB-F6E7-4044-A30E-A916A408AC0DQ48154447-F9A98BDB-2378-4C87-8C6A-6518F5CFA87DQ53218157-7C659D6D-213A-4137-8175-162CAF09EF5FQ53690201-BAF5579A-7036-403D-9E82-38934A6CD928Q84041689-1EE17FBE-799D-4A2E-AC91-27EDA388D014Q89287854-28E0A3E3-113A-4001-B40C-C493CDE0DB0B
P50
description
researcher ORCID ID = 0000-0002-7667-6088
@en
wetenschapper
@nl
name
Cesarina Giallongo
@ast
Cesarina Giallongo
@en
Cesarina Giallongo
@es
Cesarina Giallongo
@nl
type
label
Cesarina Giallongo
@ast
Cesarina Giallongo
@en
Cesarina Giallongo
@es
Cesarina Giallongo
@nl
prefLabel
Cesarina Giallongo
@ast
Cesarina Giallongo
@en
Cesarina Giallongo
@es
Cesarina Giallongo
@nl
P106
P1153
24480914100
P31
P496
0000-0002-7667-6088